-
公开(公告)号：EP3076959A1
公开(公告)日：2016-10-12
申请号：EP14868525.8
申请日：2014-12-01
发明人： BARA, Thomas , CHOBANIAN, Harry , GUO, Yan , JOSIEN, Hubert , MILLER, Michael , PIO, Barbara , PLUMMER, Christopher W. , YANG, Cangming , XIAO, Dong
IPC分类号： A61K31/075
CPC分类号： C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：EP3177614A1
公开(公告)日：2017-06-14
申请号：EP15829695.4
申请日：2015-08-05
IPC分类号： C07D409/12 , C07D493/04 , C07D215/16 , C07D215/20 , C07D413/00 , C07D307/80 , A61K31/192 , A61K31/44 , A61K31/47 , A61K31/343 , A61K31/34
CPC分类号： C07D405/14 , A61K31/335 , A61K31/397 , A61K31/4427 , A61K31/444 , A61K45/06 , C07D313/08 , C07D405/04 , C07D405/10 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译： 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，并且可用于治疗，预防和抑制由G蛋白偶联介导的疾病 受体40.本发明化合物可用于治疗2型糖尿病以及通常与该疾病相关的病症，包括肥胖和脂质紊乱，例如混合性或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症。
-
公开(公告)号：EP3076959B1
公开(公告)日：2018-07-04
申请号：EP14868525.8
申请日：2014-12-01
发明人： BARA, Thomas , CHOBANIAN, Harry , GUO, Yan , JOSIEN, Hubert , MILLER, Michael , PIO, Barbara , PLUMMER, Christopher W. , YANG, Cangming , XIAO, Dong
IPC分类号： C07C59/72 , C07C255/59 , C07D221/04 , C07D231/12 , C07D333/24 , C07D417/04 , C07D249/04 , C07D471/04 , C07D207/333 , C07D277/42 , C07D209/08 , C07D209/12 , C07D213/64 , A61K31/075 , A61K45/06 , A61P3/10
CPC分类号： C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：EP3177287A1
公开(公告)日：2017-06-14
申请号：EP15830117.6
申请日：2015-08-06
发明人： CHEN, Helen , COLLETTI, Steven L. , DEMONG, Duane , GUO, Yan , MILLER, Michael , NAIR, Anilkumar , PLUMMER, Christopher W. , XIAO, Dong , YANG, De-Yi
IPC分类号： A61K31/357
CPC分类号： C07D311/60 , A61K31/366 , A61K31/397 , A61K31/4985 , A61K45/06 , C07D405/10 , C07D405/14 , C07D413/12 , C07D413/14 , C07D451/02 , C07D471/08 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/08 , C07D491/107 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译： 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，并且可用于治疗，预防和抑制由G蛋白偶联介导的疾病 受体40.本发明化合物可用于治疗2型糖尿病以及通常与该疾病相关的病症，包括肥胖和脂质紊乱，例如混合性或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症。
-
公开(公告)号：EP3145915A1
公开(公告)日：2017-03-29
申请号：EP15795833.1
申请日：2015-05-19
发明人： BIFU, Tesfaye , BIJU, Purakkattle , BLIZZARD, Timothy A. , CHEN, Zhengxia , CLEMENTS, Matthew J. , CUI, Mingxiang , FRIE, Jessica L. , HAGMANN, William K. , HU, Bin , JOSIEN, Hubert , NAIR, Anilkumar G. , PLUMMER, Christopher W. , ZHU, Cheng
IPC分类号： C07D221/16 , C07D401/12 , C07D405/12 , A61K31/438 , A61K31/415 , A61P3/10
CPC分类号： C07D221/16 , A61K31/192 , A61K31/366 , A61K31/397 , A61K31/435 , A61K31/438 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/4985 , A61K31/538 , A61K31/55 , A61K45/06 , C07C61/39 , C07C2602/08 , C07C2603/12 , C07D215/14 , C07D401/04 , C07D401/12 , C07D405/12 , C07D413/12 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：EP2958562A1
公开(公告)日：2015-12-30
申请号：EP14754282.3
申请日：2014-02-20
发明人： BROCKUNIER, Linda L. , CHEN, Helen , CHOBANIAN, Harry R. , CLEMENTS, Matthew J. , CRESPO, Alejandro , DEMONG, Duane E. , GUO, Yan , HAGMANN, William K. , MARCANTONIO, Karen M. , MILLER, Michael , PIO, Barbara , PLUMMER, Christopher W. , XIAO, Dong
IPC分类号： A61K31/357
CPC分类号： C07D493/04 , A61K31/352 , A61K31/416 , A61K31/422 , A61K31/427 , A61K31/436 , A61K31/4433 , A61K31/444 , A61K31/497 , A61K31/538 , A61K45/06 , C07D201/00 , C07D311/04 , C07D311/28 , C07D319/20 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D413/10 , C07D417/04 , C07D491/048 , C07D491/052
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.033 秒)
